Next Biotech | Brand

Next Biotech

Add/Update information

Reviews

Tags

• Other
• Brand
• Website
• News and media website

24.01.2022 While Creso Pharma (ASX: CPH) continues to sign purchase orders and has appointed Bruce Linton as an advisor, it is a highly speculative investment, and our intent is to hold for the coming months through to Christmas to see how the company’s strategy plays out.

22.01.2022 Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.

21.01.2022 Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfolio.

21.01.2022 Backed by a new leadership team, ASX-listed biotech junior, eSense-Lab (ASX:ESE) is implementing a new business model that sees it enter joint venture agreements to quickly reach multiple revenue-generating markets.

21.01.2022 Creso Pharma (ASX: CPH) is listing on the US markets within weeks (via an OTC listing), but a similar company called MindMed is listing on the NASDAQ in 8 hours from now.

20.01.2022 Once again, medicinal cannabis company Creso Pharma (ASX: CPH) keeps pleasantly surprising us. Today they have REALLY surprised us by announcing they have acquired a Psychedelics company.

10.01.2022 Creso Pharma (ASX: CPH | FRA: 1X8) is set to distribute its range of CBD and hemp animal health anibidiol products throughout the US, following a deal signed with CERES Natural Remedies.

09.01.2022 Creso Pharma (ASX: CPH) will be the first ASX listed stock to acquire 100% of a psychedelics company. CPH is set to acquire Canada based Halucenex Life Sciences Inc., an established psychedelics company developing treatments for a range of mental illnesses.

08.01.2022 What we saw last night Minbos Resources (ASX:MNB) and Creso Pharma (ASX:CPH). Our thoughts overnight:

08.01.2022 OncoSil Medical (ASX: OSL) has received CE Mark approval to market and sell its breakthrough implantable radiotherapy treatment for pancreatic cancer within the European Union and the United Kingdom.

08.01.2022 Has medical cannabis stock $CPH Finally Turned the Corner?

07.01.2022 Creso Pharma (ASX: CPH)’s acquisition target Halucenex just picked up an extra 10g of ‘hard-to-access’ synthetic psilocybin - and now has 22.3g in total.

01.01.2022 Creso Pharma Limited (ASX: CPH) is expanding its available product line with the release of a hemp tea in Q3 2020.